CL2014001880A1 - Composición farmacéutica de quitosana glicada viscoelástica; uso para tratar el cáncer; y uso para acondicionar un neoplasma para tratamiento fotofísico e inmunológico combinado. - Google Patents
Composición farmacéutica de quitosana glicada viscoelástica; uso para tratar el cáncer; y uso para acondicionar un neoplasma para tratamiento fotofísico e inmunológico combinado.Info
- Publication number
- CL2014001880A1 CL2014001880A1 CL2014001880A CL2014001880A CL2014001880A1 CL 2014001880 A1 CL2014001880 A1 CL 2014001880A1 CL 2014001880 A CL2014001880 A CL 2014001880A CL 2014001880 A CL2014001880 A CL 2014001880A CL 2014001880 A1 CL2014001880 A1 CL 2014001880A1
- Authority
- CL
- Chile
- Prior art keywords
- photophysical
- neoplasm
- combined
- condition
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- Electromagnetism (AREA)
- Otolaryngology (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención está relacionada en general con los compuestos farmacéuticos que comprenden compuestos derivados de quitosana empleados para el tratamiento de neoplasmas, como por ejemplo, neoplasmas malignos del pulmón, tiroides y riñón, y otros tipos de neoplasmas malignos, y otros trastornos médicos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261588783P | 2012-01-20 | 2012-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014001880A1 true CL2014001880A1 (es) | 2014-11-07 |
Family
ID=48799808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014001880A CL2014001880A1 (es) | 2012-01-20 | 2014-07-15 | Composición farmacéutica de quitosana glicada viscoelástica; uso para tratar el cáncer; y uso para acondicionar un neoplasma para tratamiento fotofísico e inmunológico combinado. |
Country Status (30)
Country | Link |
---|---|
US (1) | US20150018748A1 (es) |
EP (2) | EP3831393A1 (es) |
JP (1) | JP6180436B2 (es) |
KR (5) | KR20170032490A (es) |
CN (2) | CN110038125A (es) |
AU (1) | AU2013209716B2 (es) |
BR (1) | BR112014017426B1 (es) |
CA (1) | CA2861367C (es) |
CL (1) | CL2014001880A1 (es) |
CO (1) | CO7101239A2 (es) |
CY (1) | CY1123490T1 (es) |
DK (1) | DK2804611T3 (es) |
EA (1) | EA030148B1 (es) |
EC (1) | ECSP14014778A (es) |
ES (1) | ES2829899T3 (es) |
HK (1) | HK1210019A1 (es) |
HR (1) | HRP20201647T1 (es) |
HU (1) | HUE051744T2 (es) |
IL (1) | IL233649B (es) |
LT (1) | LT2804611T (es) |
MX (1) | MX371275B (es) |
MY (1) | MY191932A (es) |
NZ (1) | NZ628433A (es) |
PE (1) | PE20142325A1 (es) |
PL (1) | PL2804611T3 (es) |
PT (1) | PT2804611T (es) |
RS (1) | RS61257B1 (es) |
SG (1) | SG11201403943TA (es) |
SI (1) | SI2804611T1 (es) |
WO (1) | WO2013109732A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11773188B2 (en) | 2012-01-20 | 2023-10-03 | Immunophotonics, Inc | Chitosan-derived compositions |
US11111316B2 (en) | 2012-01-20 | 2021-09-07 | Immunophotonics, Inc. | Chitosan-derived compositions |
US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
CN107200788B (zh) * | 2017-05-11 | 2020-04-14 | 暨南大学 | 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用 |
US20200010575A1 (en) * | 2018-07-05 | 2020-01-09 | Immunophotonics, Inc. | Semi-synthetic biopolymers for use in treating proliferative disorders |
WO2020060131A1 (ko) * | 2018-09-19 | 2020-03-26 | 주식회사 엘지화학 | LiOH를 포함하는 리튬 이차 전지용 전극, 그의 제조방법, 및 상기 전극을 포함하는 리튬 이차 전지 |
KR20210094610A (ko) | 2018-11-26 | 2021-07-29 | 포티 세븐, 인코포레이티드 | c-Kit에 대한 인간화 항체 |
WO2023028311A1 (en) * | 2021-08-27 | 2023-03-02 | Immunophotonics, Inc. | Glycated chitosans for treatment of viral infections |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US591200A (en) | 1897-10-05 | Safe-lock | ||
US4424346A (en) * | 1981-06-04 | 1984-01-03 | Canadian Patents And Development Ltd. | Derivatives of chitins, chitosans and other polysaccharides |
US5095030A (en) | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5002962A (en) | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
US5214036A (en) | 1990-03-08 | 1993-05-25 | University Of British Columbia | Benzoporphyrin derivatives for photodynamic therapy |
US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
US5283225A (en) | 1992-11-24 | 1994-02-01 | Eastman Kodak Company | Underlayer of dye-donor element for thermal dye transfer systems |
US5912000A (en) * | 1994-09-23 | 1999-06-15 | Zonagen, Inc. | Chitosan induced immunopotentiation |
US6316007B1 (en) * | 1995-04-04 | 2001-11-13 | Wound Healing Of Oklahoma | Combined physical and immunotherapy for cancer |
CN1090022C (zh) * | 1995-04-04 | 2002-09-04 | 俄克拉荷马创伤治疗所 | 通过光动力疗法与免疫佐剂联合应用治疗癌症 |
TW389694B (en) * | 1995-08-17 | 2000-05-11 | Novartis Ag | Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics |
JP4606586B2 (ja) | 1998-11-10 | 2011-01-05 | 株式会社ネーテック | 機能性キトサン誘導体 |
US20020022032A1 (en) * | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
US20040047892A1 (en) * | 2000-11-15 | 2004-03-11 | Desrosiers Eric Andre | Filler composition for soft tissue augmentation and reconstructive surgery |
US6756363B1 (en) * | 2000-11-17 | 2004-06-29 | Wound Healing Of Oklahoma, Inc. | Solutions and films of glycated chitosan |
KR20100094982A (ko) * | 2007-11-13 | 2010-08-27 | 바이오-테크널러지 제너럴 (이스라엘) 리미티드 | 점탄성 바이오폴리머의 희석식 여과 멸균 방법 |
CN101440136B (zh) * | 2008-12-12 | 2011-07-06 | 中国海洋大学 | 胺糖化几丁聚糖复合物的制备方法 |
-
2013
- 2013-01-17 DK DK13738505.0T patent/DK2804611T3/da active
- 2013-01-17 MX MX2014008702A patent/MX371275B/es active IP Right Grant
- 2013-01-17 KR KR1020177007047A patent/KR20170032490A/ko active Search and Examination
- 2013-01-17 ES ES13738505T patent/ES2829899T3/es active Active
- 2013-01-17 LT LTEP13738505.0T patent/LT2804611T/lt unknown
- 2013-01-17 CA CA2861367A patent/CA2861367C/en active Active
- 2013-01-17 KR KR1020147021861A patent/KR20140117487A/ko active Search and Examination
- 2013-01-17 KR KR1020207034027A patent/KR20200139254A/ko not_active IP Right Cessation
- 2013-01-17 HU HUE13738505A patent/HUE051744T2/hu unknown
- 2013-01-17 MY MYPI2014701927A patent/MY191932A/en unknown
- 2013-01-17 CN CN201910104579.9A patent/CN110038125A/zh active Pending
- 2013-01-17 KR KR1020187032309A patent/KR20180123727A/ko not_active Application Discontinuation
- 2013-01-17 JP JP2014553403A patent/JP6180436B2/ja active Active
- 2013-01-17 RS RS20201245A patent/RS61257B1/sr unknown
- 2013-01-17 NZ NZ628433A patent/NZ628433A/en unknown
- 2013-01-17 PT PT137385050T patent/PT2804611T/pt unknown
- 2013-01-17 EP EP20198582.7A patent/EP3831393A1/en active Pending
- 2013-01-17 SI SI201331814T patent/SI2804611T1/sl unknown
- 2013-01-17 US US14/372,586 patent/US20150018748A1/en not_active Abandoned
- 2013-01-17 EA EA201491402A patent/EA030148B1/ru not_active IP Right Cessation
- 2013-01-17 SG SG11201403943TA patent/SG11201403943TA/en unknown
- 2013-01-17 WO PCT/US2013/021903 patent/WO2013109732A2/en active Application Filing
- 2013-01-17 EP EP13738505.0A patent/EP2804611B1/en active Active
- 2013-01-17 AU AU2013209716A patent/AU2013209716B2/en active Active
- 2013-01-17 BR BR112014017426-1A patent/BR112014017426B1/pt active IP Right Grant
- 2013-01-17 PL PL13738505T patent/PL2804611T3/pl unknown
- 2013-01-17 KR KR1020227005616A patent/KR20220028153A/ko not_active Application Discontinuation
- 2013-01-17 PE PE2014001126A patent/PE20142325A1/es not_active Application Discontinuation
- 2013-01-17 CN CN201380006011.4A patent/CN104619310A/zh active Pending
-
2014
- 2014-07-15 CL CL2014001880A patent/CL2014001880A1/es unknown
- 2014-07-15 IL IL233649A patent/IL233649B/en active IP Right Grant
- 2014-07-18 CO CO14156300A patent/CO7101239A2/es unknown
- 2014-08-19 EC ECIEPI201414778A patent/ECSP14014778A/es unknown
-
2015
- 2015-10-30 HK HK15110753.9A patent/HK1210019A1/xx unknown
-
2020
- 2020-10-13 HR HRP20201647TT patent/HRP20201647T1/hr unknown
- 2020-11-06 CY CY20201101048T patent/CY1123490T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014001880A1 (es) | Composición farmacéutica de quitosana glicada viscoelástica; uso para tratar el cáncer; y uso para acondicionar un neoplasma para tratamiento fotofísico e inmunológico combinado. | |
DOP2018000026A (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
DOP2016000153A (es) | Anticuerpos y fragmentos anti-vista | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
CR20150326A (es) | Inhibidores de autotaxina | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
BR112018075166A2 (pt) | derivados de carbonucleosídeo substituídos úteis como agentes anticâncer | |
CU20160052A7 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
PE20150887A1 (es) | Compuestos de benceno sustituidos | |
UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
BR112016007891A2 (pt) | uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer | |
CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
JO3438B1 (ar) | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس | |
EA201591327A1 (ru) | Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений | |
CO2018002211A2 (es) | Piridinona dicarboxamida para su uso como inhibidores de bromodominio | |
CU20160020A7 (es) | Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer | |
CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
CU20150061A7 (es) | PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACIÓN SIN SENTIDO | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
CL2016000038A1 (es) | Piraxolo-piridinaminas sustituidas |